What short‑term opioid bridge (dose, frequency, and duration) should be prescribed for a patient with chronic cervical and lumbar pain, recent steroid injection, currently out of hydrocodone/acetaminophen 5 mg/325 mg, awaiting a transition‑of‑care appointment?

Short-Term Opioid Bridge Recommendation

For this patient with chronic cervical and lumbar pain who recently received a steroid injection and is awaiting transition-of-care, prescribe hydrocodone 5 mg/acetaminophen 325 mg, 1 tablet every 4-6 hours as needed (not scheduled), with a maximum of 5 tablets per 24 hours, for a 7-day supply only.

Rationale and Clinical Approach

The 2022 CDC guideline explicitly states that for patients already on long-term opioids requiring additional medication, nonopioid medications should be used when possible, and if additional opioids are required, they should be continued only for the duration of severe pain, returning to baseline dosage as soon as possible 1. This patient's situation—awaiting specialist evaluation with recent steroid injection—represents a temporary bridge scenario, not an indication for dose escalation or prolonged therapy.

Specific Dosing Strategy

The FDA labeling for hydrocodone/acetaminophen specifies that the usual adult dosage is one tablet every 4-6 hours as needed, with total daily dosage not exceeding 5 tablets 2. This patient was reportedly taking "two tablets daily" of what they believe was 5 mg strength, suggesting relatively low baseline requirements.

Key prescribing parameters:

• Dose: Hydrocodone 5 mg/acetaminophen 325 mg (lowest available strength)
• Frequency: Every 4-6 hours as needed only—not scheduled around-the-clock
• Maximum: 5 tablets per 24 hours (25 mg hydrocodone/1625 mg acetaminophen daily)
• Duration: 7 days maximum (35 tablets total)
• Instructions: Explicitly counsel to use only when pain is moderate-to-severe and uncontrolled by acetaminophen/ibuprofen alone

Why This Approach

The 2022 CDC guideline emphasizes prescribing opioids "as needed" rather than scheduled, and encourages tapering if opioids are taken around-the-clock for more than a few days 1. Recent evidence shows that among opioid-naive patients with acute pain, median time to opioid discontinuation was 7 days, with most patients using low doses (median 10 morphine milligram equivalents daily) 3. While this patient has chronic pain, the bridge concept applies similarly—temporary coverage until definitive intervention.

The recent steroid injection (approximately 2 weeks ago) may still be providing some benefit, as epidural steroids show efficacy for short-term pain relief in cervical and lumbar radiculopathies 4. This supports using the lowest effective opioid dose during this transition period.

Critical Caveats

Do not simply refill what the previous provider prescribed. The 2016 CDC guideline emphasizes that opioid therapy should continue only if there is clinically meaningful improvement in pain and function that outweighs risks 5. This patient's uncertain medication history ("believes it may be 5 mg") and request for a bridge suggests the previous regimen may not have been optimally effective.

Maximize nonopioid therapy concurrently:

• Continue scheduled acetaminophen (up to 3000 mg daily given chronic use)
• Continue ibuprofen if GI concerns allow (consider with food or proton pump inhibitor)
• The 2022 guideline confirms nonopioid therapies are at least as effective as opioids for neck pain, back pain, and musculoskeletal conditions 1

Document clear expectations:

• This is a one-time bridge prescription
• No early refills
• Transition-of-care provider will establish long-term pain management plan
• Leftover medication should be properly disposed (most patients report leftover opioids 3)

What NOT to Do

Avoid these common pitfalls:

• Do not prescribe scheduled (around-the-clock) dosing—this increases tolerance and dependence risk
• Do not prescribe more than 7 days—the patient has a specific TOC appointment date
• Do not prescribe higher strengths (7.5 mg or 10 mg) without documented failure of lower doses
• Do not prescribe without checking your state prescription drug monitoring program (PDMP) 5
• Do not combine with benzodiazepines if patient is taking them (increased overdose risk 5)

Safety Monitoring

Before prescribing, verify:

• PDMP shows no concerning patterns (multiple providers, early refills, high doses)
• No concurrent benzodiazepine prescriptions
• No contraindications (sleep apnea, reduced renal/hepatic function, substance use history 5)
• Patient has naloxone available or provide prescription 5

The total 7-day supply of 35 tablets (175 mg hydrocodone) represents approximately 263 morphine milligram equivalents total—well below thresholds associated with increased overdose risk when used short-term in monitored patients.